top of page

NEWS & INSIGHTS

Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

New/Newly Emerging Bio/Pharma Companies (November 2024)

We’ve identified seven (7) new or newly emerging bio/pharma companies for November 2024. To detect these new/emerging bio/pharma companies, every workday, our team uses a combination of automated and manual systems to add this data to our online biopharmIQ platform. These companies span across peptide therapies, antisense oligos, antibody chimera, scientific services and pediatric healthcare, with a majority headquartered in the United States (FIG 1.).


FIG. 1. New/Newly Emerging Bio/Pharma Companies (November 2024). 



Aizen Therapeutics

Focus: Peptide Therapies developed using AI and Computational Biology

Location: San Diego, California, United States

Insight: Aizen uses AI and computational biology to develop novel peptide therapies, positioning itself at the intersection of biology and advanced machine learning (ML) technologies.


Converge Bio

Focus: Scientific Services using AI 

Location: Tel Aviv, Israel

Insight: Converge Bio integrates generative AI and large language models (LLMs) to advance drug discovery, optimize therapeutic development, and deliver innovative solutions for the life sciences industry.


Pep2Tango Therapeutics

Focus: Peptide Therapies

Location: Potomac, Maryland, United States

Insight: Pep2Tango is developing precision peptide therapies for metabolic diseases, including a tetra-peptide agonist for obesity.


Trace Neuroscience

Focus: Antisense Oligonucleotides

Location: South San Francisco, California, United States

Insight: Focused on neurology, Trace Neuroscience uses antisense oligonucleotides (ASO) to address genetic neurological disorders such as amyotrophic lateral sclerosis (ALS).


Trogenix

Focus: Adeno-Associated Viral Vector (AAV), Immuno-Oncology

Location: Edinburgh, United Kingdom

Insight: Trogenix is utilizing AAV gene delivery technologies to develop advanced therapies for cancer treatment.


Valora Therapeutics

Focus: Antibodies (Chimeric antibody-lectin)

Location: San Diego, California, United States

Insight: Valora focuses on developing antibody-lectin chimera immunotherapies for cancer and other immune diseases.


Zarminali Health

Focus: Pediatric Care Management (Healthcare)

Location: Chicago, Illinois, United States

Insight: Zarminali provides comprehensive practice management and care coordination services for outpatient pediatric physician processes.



In conclusion, the biotech landscape for November 2024 highlights the growing role of AI in drug discovery, with companies like Aizen Therapeutics and Converge Bio leading the way. California continues to dominate as the primary biotech hub, while the majority of emerging companies are advancing targeted therapies, including peptides, antibodies, and gene-based technologies. 


Want to get notified any time a new/emerging company forms, or any time a company with your target attributes gets funded? Sign up for our Free Notification Service.


Have questions or want to schedule an online demo?


***


Article History:

RF/EV/JD/DG (12/17/24)


Not legal, investing, or tax advice.


コメント


bottom of page